Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis

Stephen J Baker; Yong-Kang Zhang; Tsutomu Akama; Agnes Lau; Huchen Zhou; Vincent Hernandez; Weimin Mao; M R K Alley; Virginia Sanders; Jacob J Plattner

doi:10.1021/jm0603724

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis

J Med Chem. 2006 Jul 27;49(15):4447-50. doi: 10.1021/jm0603724.

Authors

Stephen J Baker¹, Yong-Kang Zhang, Tsutomu Akama, Agnes Lau, Huchen Zhou, Vincent Hernandez, Weimin Mao, M R K Alley, Virginia Sanders, Jacob J Plattner

Affiliation

¹ Anacor Pharmaceuticals Inc., 1060 East Meadow Circle, Palo Alto, California 94303, USA. sbaker@anacor.com

PMID: 16854048
DOI: 10.1021/jm0603724

Abstract

A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.

MeSH terms

Administration, Topical
Antifungal Agents / chemical synthesis*
Antifungal Agents / chemistry
Antifungal Agents / pharmacology
Aspergillus fumigatus / drug effects
Boron Compounds / chemical synthesis*
Boron Compounds / chemistry
Boron Compounds / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / chemical synthesis*
Bridged Bicyclo Compounds, Heterocyclic / chemistry
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Candida / drug effects
Microbial Sensitivity Tests
Onychomycosis / drug therapy*
Structure-Activity Relationship
Trichophyton / drug effects

Substances

Antifungal Agents
Boron Compounds
Bridged Bicyclo Compounds, Heterocyclic
tavaborole